Survey of Unmet Needs in chronic myeloid leukemia (CML SUN) data signal need for amplified patient voice during treatment discussions that balance quality of life (QoL), efficacy, and tolerability goals across all lines of therapy
Novartis-Campus in Basel. (Credit: Silesia711 from Wikimedia Commons)
Novartis today announced results from its CML SUN at the 2023 European Hematology Association (EHA) Hybrid Congress.
“CML SUN was designed to address critical unanswered questions amongst people living with chronic myeloid leukemia and physicians, such as approach to treatment options, differences in efficacy and tolerability priorities, as well as effectiveness around communicating goals to one another,” says CML SUN Steering Committee member and study author Fabian Lang, MD, Goethe University Hospital, Frankfurt, Germany. “As CML has, in many ways, become a chronic disease thanks to available treatments, it’s important to understand patient and physician priorities, especially as they change across lines of therapy. These CML SUN insights will help us continue to evolve how CML is managed.”
Across 11 countries, similar themes emerged from the data around treatment goals, joint decision-making, and treatment satisfaction. Specifically:
- In their goals for treatment, patients focus on stopping or slowing disease progression, maintaining/improving QoL, and minimizing/managing side effects, while physicians place greater emphasis on treatment efficacy.
- Across lines of therapy, 48% to 66% of physicians report presenting only one treatment option to patients, while 39% to 43% of patients report only receiving information about one treatment from their physician.
- Only 19% to 26% of patients state that treatment decisions are discussed and decided together with their physician, while 44% to 48% of physicians report making treatment decisions with little to no input from the patient across lines of therapy.
- Most patients and physicians report being satisfied with the efficacy of current treatments. Still, many patients report treatments affect QoL, including physical or emotional fatigue, difficulty in exercising and maintaining social lives, and constant worry/stress about treatment effectiveness.
“People living with chronic myeloid leukemia must be able to have open and honest conversations with their doctors about their treatment goals, how medication side effects impact their lives, as well as their emotional and mental well-being,” explained Lisa Machado, CML SUN Steering Committee member, founder of the Canadian CML Network and executive producer of Healthing.ca. “We have come a long way in terms of how we treat CML, with innovative therapies making it possible for people to live longer and better lives with this disease. But there’s still more work to be done, especially when it comes to ensuring the relationships between doctors and patients are based on shared decision-making, a clear understanding of quality of life needs and expectations for the future.”
These results are based on data from Australia, Brazil, Canada, France, Germany, Italy, Japan, South Korea, Spain, UK, and USA. Final analyses of the data are expected to be published later in the year.
Source: Company Press Release